ORPOF (OSE Immunotherapeutics) Current Accrued Expense: $0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ORPOF OSE Immunotherapeutics SA ORPOF
40 GF Score
Price $4.43
GF Value $1.93
! 6 Warning Signs
View Full Analysis

What is OSE Immunotherapeutics Current Accrued Expense?

OSE Immunotherapeutics ORPOF 40 Current Accrued Expense is $0.00 Mil as of Dec. 2025. GuruFocus rates ORPOF with a GF Score™ of 40/100 and a GF Value™ of $1.93. The stock has 6 warning signs investors should review.

OSE Immunotherapeutics's Current Accrued Expense for the quarter that ended in Dec. 2025 was $0.00 Mil.

OSE Immunotherapeutics Current Accrued Expense Related Terms

OSE Immunotherapeutics Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for OSE Immunotherapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OSE Immunotherapeutics Current Accrued Expense Chart

OSE Immunotherapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

OSE Immunotherapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ORPOF
40GF Score
OSE Immunotherapeutics SA ORPOF
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OSE Immunotherapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $0.00 Mil mean?
OSE Immunotherapeutics (ORPOF) has a Current Accrued Expense of $0.00 Mil as of Dec. 2025. Current Accrued Expense records the total amount of accrued expenses. View historical data on OSE Immunotherapeutics and its competitors.
Is OSE Immunotherapeutics' Current Accrued Expense too high?
OSE Immunotherapeutics' current Current Accrued Expense is $0.00 Mil. Overall, OSE Immunotherapeutics has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does OSE Immunotherapeutics' Current Accrued Expense compare to VRTX and REGN?
OSE Immunotherapeutics' Current Accrued Expense of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on OSE Immunotherapeutics and its competitors. OSE Immunotherapeutics's current Current Accrued Expense is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OSE Immunotherapeutics stock overvalued right now?
OSE Immunotherapeutics (ORPOF) has a current Current Accrued Expense of $0.00 Mil. The stock's GF Value™ is $1.93, compared to a current price of $4.43 — trading 129.5% above its estimated fair value. The current Current Accrued Expense is $0.00 Mil. OSE Immunotherapeutics' overall GF Score™ is 40/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For OSE Immunotherapeutics (ORPOF), the current Current Accrued Expense is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is OSE Immunotherapeutics (ORPOF) Overvalued in 2026?

Based on GuruFocus' analysis, OSE Immunotherapeutics stock appears to be overvalued. The current stock price of $4.43 is trading 129.5% above its estimated GF Value™ of $1.93.

Key valuation signals for ORPOF:

  • Current Accrued Expense: $0.00 Mil
  • GF Value™: $1.93 vs. price of $4.43 (129.5% above fair value)
  • GF Score™: 40/100 with 6 warning signs

No single metric tells the full story. See the ORPOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

OSE Immunotherapeutics Business Description

Address 22, Boulevard Benoni Goullin, Nantes, FRA, 44200
OSE Immunotherapeutics SA is a France-based biotechnology company focused on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. The product portfolio of the company comprises Tedopi, OSE-172, OSE-703, FR104 and OSE-127.
40GF Score

Get the complete analysis for ORPOF

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.43
Price
$1.93
GF Value